Last reviewed · How we verify
Actinium Ac 225-DOTA-Daratumumab
Targeting CD38 with a radioligand
Targeting CD38 with a radioligand Used for Multiple myeloma.
At a glance
| Generic name | Actinium Ac 225-DOTA-Daratumumab |
|---|---|
| Also known as | 225Ac-DOTA-Daratumumab; [225Ac]-DOTA-Daratumumab, 225Ac-DOTA-Daratumumab, [225Ac]-DOTA-Daratumumab |
| Sponsor | City of Hope Medical Center |
| Drug class | CD38-targeting radioligand therapy |
| Target | CD38 |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 1 |
Mechanism of action
Actinium Ac 225-DOTA-Daratumumab is a radioligand therapy that targets CD38, a transmembrane glycoprotein involved in the immune response. By binding to CD38, the drug delivers alpha-particle radiation to cancer cells, leading to cell death.
Approved indications
- Multiple myeloma
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Fatigue
- Anemia
Key clinical trials
- Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple Myeloma (PHASE1)
- 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Actinium Ac 225-DOTA-Daratumumab CI brief — competitive landscape report
- Actinium Ac 225-DOTA-Daratumumab updates RSS · CI watch RSS
- City of Hope Medical Center portfolio CI